Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105174 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL29069175 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL377199 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL29039966 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL29039969 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL15519970 | 0.90 | PPM1D (0.32) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL31104974 | 0.89 | PPM1D (0.34) | PPM1DUSP2SMN1; SMN2 | |
| SCHEMBL1269216 | 0.88 | PPM1D (0.31) | PPM1D | |
| SCHEMBL1269218 | 0.88 | PPM1D (0.31) | PPM1D | |
| SCHEMBL14348107 | 0.88 | PPM1D (0.31) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514864-B | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-116514864-A | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116514864-B | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116514864-B | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116514864-B | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4405352-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-117980303-A | Novel compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-116514864-A | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116514864-A | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116514864-A | Preparation method of (2S, 4R) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2708540-A1 | PYRIMIDO-DIAZEPINONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-7998959-B2 | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1696919-A4 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1696919-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005060665-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | PPM1D 2622/4885NR1H2 666/4885USP2 4281/4885 |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | PPM1D 3443/4885NR1H2 1206/4885USP2 3717/4885 |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | PPM1D 2582/4885NR1H2 971/4885USP2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.